Shares

41 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$21.0 - $29.1 $4,872 - $6,751
-232 Reduced 5.33%
4,123 $91,000
Q3 2023

Nov 14, 2023

BUY
$22.33 - $29.92 $6,319 - $8,467
283 Added 6.95%
4,355 $97,000
Q2 2023

Aug 10, 2023

BUY
$20.96 - $26.99 $85,349 - $109,903
4,072 New
4,072 $103,000
Q4 2022

Jun 14, 2023

BUY
$15.31 - $29.94 $69,308 - $135,538
4,527 New
4,527 $107 Million
Q3 2022

Jun 14, 2023

BUY
$16.58 - $27.9 $75,057 - $126,303
4,527 New
4,527 $75.1 Million
Q2 2022

Jun 20, 2023

BUY
$15.45 - $29.52 $69,942 - $133,637
4,527 New
4,527 $90,000
Q1 2022

Jun 20, 2023

BUY
$21.94 - $42.51 $99,322 - $192,442
4,527 New
4,527 $124,000
Q1 2022

Mar 30, 2023

SELL
$21.94 - $42.51 $293,842 - $569,336
-13,393 Reduced 74.74%
4,527 $124,000
Q1 2022

May 12, 2022

SELL
$21.94 - $42.51 $293,842 - $569,336
-13,393 Reduced 74.74%
4,527 $125,000
Q4 2021

Jun 21, 2023

BUY
$36.09 - $53.79 $646,732 - $963,916
17,920 New
17,920 $738,000
Q3 2021

Jun 21, 2023

BUY
$35.62 - $52.97 $638,310 - $949,222
17,920 New
17,920 $832,000
Q3 2021

Mar 30, 2023

SELL
$35.62 - $52.97 $49,868 - $74,158
-1,400 Reduced 7.25%
17,920 $832,000
Q3 2021

Nov 15, 2021

SELL
$35.62 - $52.97 $49,868 - $74,158
-1,400 Reduced 7.25%
17,920 $832,000
Q2 2021

Mar 30, 2023

BUY
$32.94 - $56.62 $40,878 - $70,265
1,241 Added 6.86%
19,320 $772,000
Q2 2021

Aug 16, 2021

BUY
$32.94 - $56.62 $635,807 - $1.09 Million
19,302 Added 107233.33%
19,320 $772,000
Q1 2021

Jun 26, 2023

BUY
$44.47 - $81.38 $803,973 - $1.47 Million
18,079 New
18,079 $972 Million
Q1 2021

Mar 30, 2023

BUY
$44.47 - $81.38 $56,966 - $104,247
1,281 Added 7.63%
18,079 $971,000
Q1 2021

May 14, 2021

SELL
$44.47 - $81.38 $746,206 - $1.37 Million
-16,780 Reduced 99.89%
18 $972,000
Q4 2020

Jun 22, 2023

BUY
$32.49 - $61.88 $545,767 - $1.04 Million
16,798 New
16,798 $822,000
Q4 2020

Mar 30, 2023

BUY
$32.49 - $61.88 $7,505 - $14,294
231 Added 1.39%
16,798 $822,000
Q4 2020

Feb 16, 2021

BUY
$32.49 - $61.88 $7,505 - $14,294
231 Added 1.39%
16,798 $822,000
Q3 2020

Jun 26, 2023

BUY
$26.73 - $35.67 $442,835 - $590,944
16,567 New
16,567 $538,000
Q3 2020

Mar 30, 2023

BUY
$26.73 - $35.67 $26,168 - $34,920
979 Added 6.28%
16,567 $538,000
Q3 2020

Nov 13, 2020

BUY
$26.73 - $35.67 $26,168 - $34,920
979 Added 6.28%
16,567 $538,000
Q2 2020

Jun 26, 2023

BUY
$19.49 - $28.11 $303,810 - $438,178
15,588 New
15,588 $403,000
Q2 2020

Mar 30, 2023

BUY
$19.49 - $28.11 $1,403 - $2,023
72 Added 0.46%
15,588 $403,000
Q2 2020

Aug 14, 2020

BUY
$19.49 - $28.11 $1,403 - $2,023
72 Added 0.46%
15,588 $404,000
Q1 2020

Jul 12, 2023

BUY
$16.13 - $30.17 $250,273 - $468,117
15,516 New
15,516 $377,000
Q4 2019

Jul 12, 2023

BUY
$20.78 - $29.99 $322,422 - $465,324
15,516 New
15,516 $433,000
Q3 2019

Jul 12, 2023

BUY
$23.87 - $30.93 $370,366 - $479,909
15,516 New
15,516 $372,000
Q3 2019

Mar 30, 2023

BUY
$23.87 - $30.93 $118,681 - $153,783
4,972 Added 47.15%
15,516 $372,000
Q3 2019

Nov 14, 2019

BUY
$23.87 - $30.93 $118,681 - $153,783
4,972 Added 47.15%
15,516 $372,000
Q2 2019

Jul 12, 2023

BUY
$22.1 - $28.56 $233,022 - $301,136
10,544 New
10,544 $300,000
Q1 2019

Jul 13, 2023

BUY
$12.0 - $25.76 $126,528 - $271,613
10,544 New
10,544 $263,000
Q1 2019

Mar 30, 2023

BUY
$12.0 - $25.76 $72,204 - $154,997
6,017 Added 132.91%
10,544 $263,000
Q1 2019

May 16, 2019

SELL
$12.0 - $25.76 $223,872 - $480,578
-18,656 Reduced 63.89%
10,544 $263,000
Q1 2019

May 15, 2019

BUY
$12.0 - $25.76 $223,872 - $480,578
18,656 Added 176.93%
29,200 $1.4 Million
Q4 2018

Jul 13, 2023

BUY
$9.15 - $14.85 $96,477 - $156,578
10,544 New
10,544 $132,000
Q4 2018

Feb 14, 2019

BUY
$9.15 - $14.85 $75,350 - $122,289
8,235 Added 356.65%
10,544 $133,000
Q3 2018

Jul 13, 2023

BUY
$9.55 - $12.64 $100,695 - $133,276
10,544 New
10,544 $101 Million
Q3 2018

Nov 14, 2018

BUY
$9.55 - $12.64 $22,050 - $29,185
2,309 New
2,309 $22,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $3.14B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.